123 related articles for article (PubMed ID: 37184495)
1. TACROLIMUS FOR IMMUNOSUPPRESSION IN PATIENTS WITH NONINFECTIOUS INTERMEDIATE, POSTERIOR, OR PANUVEITIDES.
Jabs DA; Thorne JE; Wilkins CS; Habbu KA; Berkenstock MK; Burkholder BM; Chaon BC; Deobhakta A
Retina; 2023 Sep; 43(9):1480-1486. PubMed ID: 37184495
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate for ocular inflammatory diseases.
Gangaputra S; Newcomb CW; Liesegang TL; Kaçmaz RO; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Suhler EB; Thorne JE; Foster CS; Kempen JH;
Ophthalmology; 2009 Nov; 116(11):2188-98.e1. PubMed ID: 19748676
[TBL] [Abstract][Full Text] [Related]
3. Effect of Corticosteroid-Sparing Treatment With Mycophenolate Mofetil vs Methotrexate on Inflammation in Patients With Uveitis: A Randomized Clinical Trial.
Rathinam SR; Gonzales JA; Thundikandy R; Kanakath A; Murugan SB; Vedhanayaki R; Lim LL; Suhler EB; Al-Dhibi HA; Doan T; Keenan JD; Rao MM; Ebert CD; Nguyen HH; Kim E; Porco TC; Acharya NR;
JAMA; 2019 Sep; 322(10):936-945. PubMed ID: 31503307
[TBL] [Abstract][Full Text] [Related]
4. Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis.
; Kempen JH; Altaweel MM; Holbrook JT; Sugar EA; Thorne JE; Jabs DA
JAMA; 2017 May; 317(19):1993-2005. PubMed ID: 28477440
[TBL] [Abstract][Full Text] [Related]
5. Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.
Suhler EB; Thorne JE; Mittal M; Betts KA; Tari S; Camez A; Bao Y; Joshi A
Ophthalmology; 2017 Dec; 124(12):1799-1807. PubMed ID: 28689898
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and tolerance of tacrolimus for the treatment of uveitis.
Hogan AC; McAvoy CE; Dick AD; Lee RW
Ophthalmology; 2007 May; 114(5):1000-6. PubMed ID: 17467532
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of tacrolimus versus tacrolimus and prednisone for the maintenance of disease remission in noninfectious uveitis.
Lee RW; Greenwood R; Taylor H; Amer R; Biester S; Heissigerova J; Forrester JV; Dick AD
Ophthalmology; 2012 Jun; 119(6):1223-30. PubMed ID: 22381809
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies.
Nguyen QD; Merrill PT; Sepah YJ; Ibrahim MA; Banker A; Leonardi A; Chernock M; Mudumba S; Do DV
Ophthalmology; 2018 Dec; 125(12):1984-1993. PubMed ID: 30060978
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
[TBL] [Abstract][Full Text] [Related]
10. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.
Nussenblatt RB; Peterson JS; Foster CS; Rao NA; See RF; Letko E; Buggage RR
Ophthalmology; 2005 May; 112(5):764-70. PubMed ID: 15878055
[TBL] [Abstract][Full Text] [Related]
11. Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Suhler EB; Jaffe GJ; Fortin E; Lim LL; Merrill PT; Dick AD; Brezin AP; Nguyen QD; Thorne JE; Van Calster J; Cimino L; Adan A; Goto H; Kaburaki T; Kramer M; Vitale AT; Kron M; Song AP; Liu J; Pathai S; Douglas KM; Schlaen A; Muccioli C; Van Velthoven MEJ; Zierhut M; Rosenbaum JT
Ophthalmology; 2021 Jun; 128(6):899-909. PubMed ID: 33157077
[TBL] [Abstract][Full Text] [Related]
12. Success with single-agent immunosuppression for multifocal choroidopathies.
Goldberg NR; Lyu T; Moshier E; Godbold J; Jabs DA
Am J Ophthalmol; 2014 Dec; 158(6):1310-7. PubMed ID: 25194229
[TBL] [Abstract][Full Text] [Related]
13. Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.
Sheppard J; Joshi A; Betts KA; Hudgens S; Tari S; Chen N; Skup M; Dick AD
JAMA Ophthalmol; 2017 Jun; 135(6):511-518. PubMed ID: 28426849
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine for ocular inflammatory diseases.
Pasadhika S; Kempen JH; Newcomb CW; Liesegang TL; Pujari SS; Rosenbaum JT; Thorne JE; Foster CS; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Suhler EB
Am J Ophthalmol; 2009 Oct; 148(4):500-509.e2. PubMed ID: 19570522
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Treatment with Biological Agents in Eyes with Refractory, Active, Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.
Al-Janabi A; El Nokrashy A; Sharief L; Nagendran V; Lightman S; Tomkins-Netzer O
Ophthalmology; 2020 Mar; 127(3):410-416. PubMed ID: 31607412
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression for the Uveitides.
Jabs DA
Ophthalmology; 2018 Feb; 125(2):193-202. PubMed ID: 28942074
[TBL] [Abstract][Full Text] [Related]
17. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis.
Rathinam SR; Babu M; Thundikandy R; Kanakath A; Nardone N; Esterberg E; Lee SM; Enanoria WT; Porco TC; Browne EN; Weinrib R; Acharya NR
Ophthalmology; 2014 Oct; 121(10):1863-70. PubMed ID: 24917273
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide for ocular inflammatory diseases.
Pujari SS; Kempen JH; Newcomb CW; Gangaputra S; Daniel E; Suhler EB; Thorne JE; Jabs DA; Levy-Clarke GA; Nussenblatt RB; Rosenbaum JT; Foster CS
Ophthalmology; 2010 Feb; 117(2):356-65. PubMed ID: 19969366
[TBL] [Abstract][Full Text] [Related]
19. The safety and efficacy of noncorticosteroid triple immunosuppressive therapy in the treatment of refractory chronic noninfectious uveitis in childhood.
Little JA; Sen ES; Strike H; Hinchcliffe A; Guly CM; Lee RW; Dick AD; Ramanan AV
J Rheumatol; 2014 Jan; 41(1):136-9. PubMed ID: 24085549
[TBL] [Abstract][Full Text] [Related]
20. Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study.
; Kempen JH; Altaweel MM; Drye LT; Holbrook JT; Jabs DA; Sugar EA; Thorne JE
Ophthalmology; 2015 Oct; 122(10):1967-75. PubMed ID: 26298715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
